Somatrogon FDA Approval Status
FDA Approved: No
Generic name: somatrogon
Company: Pfizer Inc.
Treatment for: Pediatric Growth Hormone Deficiency
Somatrogon is an investigational, long-acting human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency (GHD).
Development Timeline for somatrogon
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.